The clinical efficacy of biological immunomodulators in SARS-CoV-2- associated multisystem inflammatory syndrome in children: A systematic review
Authorea (Authorea)(2023)
摘要
The clinical efficacy of biological immunomodulators in patients refractory to standard therapy of intravenous immunoglobulin (IVIg) and glucocorticoids remains unclear. This review aimed to outline real-world data on the clinical outcomes of biological immunomodulators using Ovid-Medline, EMBASE, Cochrane CDSR, and the Korean database, KMBASE from September 2021 to August 2022. Among 251 studies , 10 were selected, of which two were observational studies with control groups receiving a standard therapy of IVIg and/or glucocorticoids. In total, 145 patients were treated with biological agents. In the first study with a control group, anakinra-treated group exhibited a lower left ventricular ejection fraction at baseline (54% vs. 60%, P = 0.08). Patients in the infliximab group of second study showed lesser additional treatment requirements (31% vs. 65%, P = 0.01), and lower rate of newly developed left ventricular dysfunction (4% vs. 20%, P = 0.05). The remaining eight single-arm studies did not report the clinical outcomes of each type of biological immunomodulator individually, limiting further interpretation. The findings of this review imply the potential of biological immunomodulators as a feasible therapeutic option for refractory MIS-C.
更多查看译文
关键词
multisystem inflammatory syndrome,inflammatory syndrome,biological immunomodulators,sars-cov
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要